Clinical trials reveal tirzepatides edge in achieving higher weight loss percentages, often exceeding 20% in non-diabetic obesity patients, while mazdutide shows great results, with up to 14% weight reduction in phase II studies
Initial assessment typically includes: Detailed history: Your doctor will ask about B12 supplementation, dietary habits, alcohol consumption, medications, and symptoms suggesting liver disease, kidney disease, or malignancy Physical examination: Looking for signs of liver disease (hepatomegaly, jaundice), lymphadenopathy, splenomegaly, or other abnormalities Medication review: Identifying any supplements or medications that might explain the elevation First-line investigations commonly include: Repeat B12 measurement: Confirming persistent elevation after stopping supplements (if applicable), ideally using the same laboratory Full blood count (FBC): Assessing for anaemia, polycythaemia, or abnormal white cell counts that might suggest haematological disorders Peripheral blood film: May be requested if blood count abnormalities are present Liver function tests: Evaluating for hepatic disease through ALT, AST, alkaline phosphatase, bilirubin, and albumin Renal function tests: Measuring creatinine and estimated glomerular filtration rate (eGFR) Inflammatory markers: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) if inflammation is suspected Further investigations may be arranged based on initial findings: Haematology referral: If FBC abnormalities suggest myeloproliferative disorders (e.g., raised haemoglobin, platelets), specialist assessment with JAK2 mutation testing or bone marrow examination may be necessary Liver imaging: Ultrasound, CT, or MRI scanning if liver disease or hepatic malignancy is suspected Additional blood tests: Including lactate dehydrogenase (LDH) if clinically indicated If results remain unexplained, discussion with the laboratory about possible macro-B12 or assay interference may be helpful
As long as storage temperature remains below this glass transition point, the peptide molecules stay locked in place, unable to undergo the chemical reactions that would degrade them
the scopolamine treated group = 1 14.7 s
